AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer
0
조회
0
다운로드
0
인용
0
참고문헌
초록
The transcript encoding Antizyme Inhibitor 1 (AZIN1) is frequently edited in various cancers, and this editing is associated with enhanced tumor aggressiveness. After comparison of wild-type AZIN1 (wtAZIN1) and edited AZIN1 (edAZIN1, which contains a Ser367Gly substitution), we report differential binding of edAZIN1 to a small set of proteins; specifically, edAZIN1 binds to alpha-smooth muscle actin (ACTA2), gamma actin 1 (ACTG1), and myosin9, whereas wtAZIN1 does not. This binding enables nuclear translocation of edAZIN1. In contrast to overexpression of edAZIN1 and, to a lesser extent, (editable) wtAZIN1, overexpression of an uneditable AZIN1 allele does not promote a cellular phenotype associated with increased tumorigenicity. In patients, both editing and nuclear localization of AZIN1 are common and are associated with tumor aggressiveness, i.e., a higher Gleason score, higher genomic instability, and a shorter progression-free survival time. In conclusion, the data indicate that binding of edAZIN1 to the actin/myosin9 complex supports its nuclear translocation, leading to enhanced cellular aggressiveness, and is associated with worse prostate cancer outcomes.
Abstract
The transcript encoding Antizyme Inhibitor 1 (AZIN1) is frequently edited in various cancers, and this editing is associated with enhanced tumor aggressiveness. After comparison of wild-type AZIN1 (wtAZIN1) and edited AZIN1 (edAZIN1, which contains a Ser367Gly substitution), we report differential binding of edAZIN1 to a small set of proteins; specifically, edAZIN1 binds to alpha-smooth muscle actin (ACTA2), gamma actin 1 (ACTG1), and myosin9, whereas wtAZIN1 does not. This binding enables nuclear translocation of edAZIN1. In contrast to overexpression of edAZIN1 and, to a lesser extent, (editable) wtAZIN1, overexpression of an uneditable AZIN1 allele does not promote a cellular phenotype associated with increased tumorigenicity. In patients, both editing and nuclear localization of AZIN1 are common and are associated with tumor aggressiveness, i.e., a higher Gleason score, higher genomic instability, and a shorter progression-free survival time. In conclusion, the data indicate that binding of edAZIN1 to the actin/myosin9 complex supports its nuclear translocation, leading to enhanced cellular aggressiveness, and is associated with worse prostate cancer outcomes.
참고문헌 (31)
- Ciriello, G., "Emerging landscape of oncogenic signatures across human cancers", Nat. Genet, 45, pp.1127~1133 (2013)
- Kumar-Sinha, C., "Evidence of recurrent gene fusions in common epithelial tumors", Trends Mol. Med, 12, pp.529~536 (2006)
- Tomlins, S. A., "Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer", Science, 310, pp.644~648 (2005)
- Gallo, A., "RNA editing enters the limelight in cancer", Nat. Med, 19, pp.130~131 (2013)
- Xu, L. D., "ADAR1 Editing and its Role in Cancer", Genes(Basel), 10, pp.12~ (2018)
- Han, L., "The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers", Cancer Cell, 28, pp.515~528 (2015)
- Chen, L., "Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma", Nat. Med, 19, pp.209~216 (2013)
- Qin, Y. R., "Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma", Cancer Res, 74, pp.840~851 (2014)
- Shigeyasu, K., "AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer", JCI Insight, 3, pp.e99976~ (2018)
- Takeda, S., "Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer", Cancer Lett, 444, pp.127~135 (2019)
- Okugawa, Y., "Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer", J. Transl. Med, 16, pp.366~ (2018)
- Hu, X., "RNA editing of AZIN1 induces the malignant progression of nonsmall-cell lung cancers", Tumour Biol, 39, pp.1010428317700001~ (2017)
- Chung, H., "Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown", Cell, 172, pp.811~824.e814 (2018)
- Bryksin, A. V., "Overlap extension PCR cloning: a simple and reliable way to create recombinant plasmids", Biotechniques, 48, pp.463~465 (2010)
- Cryan, L. M., "Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay", J. Biomol. Screen, 18, pp.714~725 (2013)
- Ghalali, A., "Developing a novel FRET assay, targeting the binding between Antizyme-AZIN", Sci. Rep, 9, pp.4632~ (2019)
- Kamitani, M., "Lasy-Seq : a high-throughput library preparation method for RNA-Seq and its application in the analysis of plant responses to fluctuating temperatures", Sci. Rep, 9, pp.7091~ (2019)
- Epstein, J. I., "The 2014 International Society of Urological Pathology (ISUP)Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System", Am. J. Surg. Pathol, 40, pp.244~252 (2016)
- Leung, Y. K., "Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion", Endocr. Relat. Cancer, 17, pp.675~689 (2010)
- Cancer Genome Atlas Research Network, "The Molecular Taxonomy of Primary Prostate Cancer", Cell, 163, pp.1011~1025 (2015)
- Gao, J., "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci. Signal, 6, pp.pl1~ (2013)
- Elfandy, H., "Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate", Mol. Cancer Res, 17, pp.446~456 (2019)
- de Lanerolle, P., "Nuclear actin and myosins at a glance", J. Cell Sci, 125, pp.4945~4949 (2012)
- de Lanerolle, P., "Nuclear actin and myosins : life without filaments", Nat. Cell Biol, 13, pp.1282~1288 (2011)
- Allingham, J. S., "The structural basis of blebbistatin inhibition and specificity for myosin II", Nat. Struct. Mol. Biol, 12, pp.378~379 (2005)
- Wu, H. Y., "Structural basis of antizyme-mediated regulation of polyamine homeostasis", Proc. Natl Acad. Sci. U. S. A, 112, pp.11229~11234 (2015)
- Olsen, R. R., "Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo", Amino Acids, 42, pp.549~558 (2012)
- Eisenberg, E., "A-to-I RNA editing-immune protector and transcriptome diversifier", Nat. Rev. Genet, 19, pp.473~490 (2018)
- Halder, D., "Nonmuscle myosin IIA and IIB differentially modulate migration and alter gene expression in primary mouse tumorigenic cells", Mol. Biol. Cell, 30, pp.1463~1476 (2019)
- Schramek, D., "Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas", Science, 343, pp.309~313 (2014)
- Wang, B., "MYH9 Promotes Growth and Metastasis via Activation of MAPK", AKT Signaling in Colorectal Cancer, 2019, pp.10, 874~884